🧪 AOD-9604

What Is AOD-9604?

AOD-9604 is a synthetic peptide consisting of 16 amino acids, derived from the C-terminal sequence of human growth hormone (hGH), specifically residues 177–191, with an added N-terminal tyrosine for stability [citation:4][citation:7]. It was originally developed by Metabolic Pharmaceuticals in the late 1990s as a potential anti-obesity agent [citation:5].

The hypothesis behind AOD-9604 was that the lipolytic (fat-burning) activity of full-length hGH could be isolated from its diabetogenic side effects, such as insulin resistance and elevated IGF-1 [citation:4][citation:8]. Research by Ng and colleagues in the 1990s and 2000s demonstrated that this fragment could reduce weight gain and adipocyte size in obese Zucker rats without causing glucose intolerance [citation:4][citation:10].

Proposed Mechanism of Action

AOD-9604 is believed to exert its effects directly on adipose tissue through several mechanisms:

• Stimulates Lipolysis: Activates beta-3 adrenergic receptors in fat cells, triggering the breakdown of stored triglycerides into free fatty acids for energy [citation:8].
• Inhibits Lipogenesis: Suppresses the formation of new fat from non-fat precursors, reducing fat accumulation [citation:1][citation:8].
• No IGF-1 Elevation: Unlike full hGH, AOD-9604 does not raise circulating IGF-1 levels, theoretically reducing the risk of anabolic or proliferative effects [citation:8][citation:10].
• No Insulin Resistance: Studies have shown that AOD-9604 does not impair glucose tolerance or insulin sensitivity, a key advantage over hGH [citation:1][citation:10].

Preclinical Evidence

Before entering human trials, AOD-9604 showed encouraging results in animal models.

• Rodent Studies: Multiple studies demonstrated that chronic administration of synthetic hGH fragment 177-191 reduced cumulative body weight gain and adipose tissue mass in obese mice and Zucker rats [citation:4].
• Lipolysis and Lipogenesis: The fragment was shown to stimulate lipolysis and inhibit lipogenesis without affecting glucose levels [citation:1][citation:7].
• No Glucose Intolerance: Unlike full hGH, which can depress glucose oxidation and elevate plasma glucose, AOD-9604 did not cause hyperglycemia or affect insulin sensitivity in animals [citation:4][citation:10].
• GRAS Status: AOD-9604 was determined to be “Generally Recognized As Safe” (GRAS) by an expert panel for use as a dietary supplement ingredient—a designation that speaks to safety, not efficacy [citation:2][citation:7].

Clinical Trial History

Between 2001 and 2006, six human clinical trials were conducted with AOD-9604, involving 893 healthy, mostly obese adults [citation:7].

🔬 Key Studies

• Phase I (IV): Single-dose dose-escalation study (25–400 µg/kg) in healthy males. Well-tolerated; no significant changes in IGF-1 or glucose [citation:7].
• Phase IIa (Oral, Single & Multiple Dose): Studies with 9–54 mg oral doses. Showed acceptable safety profile; no significant changes in IGF-1 or glucose [citation:7].
• Phase IIb (METAOD005 – 12 weeks): 300 patients, 1–30 mg daily. An earlier 12-week trial showed a 2.6 kg weight loss vs. 0.8 kg with placebo [citation:1].
• Phase IIb (METAOD006 – 24 weeks): The pivotal trial—502 patients, 0.25–1 mg daily. This trial failed to meet its primary weight-loss endpoint [citation:4][citation:5].

The Phase 2b Failure

The pivotal Phase 2b trial (METAOD006) is the central fact in the AOD-9604 story. It was adequately powered, placebo-controlled, and designed to detect weight loss over 24 weeks in 502 obese subjects [citation:4][citation:5].

• Primary Endpoint: The trial failed to show a statistically significant difference in weight loss between AOD-9604 and placebo [citation:4][citation:5].
• Development Termination: Following the outcome, Metabolic Pharmaceuticals did not advance AOD-9604 to Phase 3 trials [citation:4]. The Australian Therapeutic Goods Administration (TGA) rejected an obesity indication [citation:4].
• Publication Status: The primary publication from the pivotal Phase 2b trial was never submitted to a peer-reviewed journal—the failure is documented via reviews and company disclosures [citation:4].
• Primary Publication: A 2013 review by Misra documented the failure, noting that development was terminated after the 536-patient trial failed to induce significant weight loss [citation:4].

Safety & Tolerability

Despite the efficacy failure, the safety profile of AOD-9604 appeared relatively favorable in the clinical trials.

• Excellent Safety Profile: A review of six clinical trials concluded that AOD-9604 displayed a safety profile indistinguishable from placebo [citation:7][citation:10].
• No Immunogenicity: Anti-AOD-9604 antibodies were not detected in any patients tested in the long-term studies [citation:2][citation:7].
• No IGF-1 Elevation: No significant changes in IGF-1 levels across treatment groups [citation:11].
• No Glucose Effects: No negative impact on glucose tolerance or insulin sensitivity [citation:10].
• Serious Adverse Events: SAEs reported in the 24-week study included basal cell carcinoma, lipoma, breast cancer, and malignant melanoma—but investigators deemed these unrelated to treatment [citation:11].

Regulatory Status

AOD-9604 occupies a complex regulatory position.

• FDA Category 2: As of April 2026, AOD-9604 is classified as an FDA Category 2 bulk drug substance—meaning compounding is restricted pending further review [citation:4].
• No FDA Approval: AOD-9604 has never held an FDA-approved drug indication [citation:4][citation:9].
• TGA Rejected: The Australian Therapeutic Goods Administration rejected an obesity indication following the Phase 2b failure [citation:4].
• WADA Banned: AOD-9604 is prohibited in sport by the World Anti-Doping Agency (WADA) at all times, with a urine test available for detection [citation:4][citation:9].
• Not in Pharmacopeias: No monograph listings in European, Chinese, Indian, or Japanese pharmacopeias [citation:5].

Current Availability

Despite its regulatory status, AOD-9604 continues to be marketed in certain circles.

• Compounding Restricted: As a Category 2 substance, compounding of AOD-9604 is restricted in the U.S. under Section 503A [citation:4].
• Wellness Clinics: Some medical spas and wellness clinics continue to offer AOD-9604 off-label as a “metabolic adjunct” [citation:5][citation:12].
• Gray-Market Products: Unregulated injectable products labeled as AOD-9604 continue to circulate online, but with no oversight on identity, purity, or potency [citation:4].
• Recall History: In 2021, several lots of 3 mg injectable peptide were recalled due to concerns that the vials may not be sterile [citation:9].
• Adjunct Only: Clinics that prescribe it emphasize that it is an adjunct—not a stand-alone treatment—and that results are modest without aligned diet and exercise [citation:12].

AOD-9604 is a cautionary tale in the world of peptide therapeutics: compelling preclinical data and an elegant mechanism do not guarantee clinical success. After more than two decades of research, a pivotal Phase 2b trial failed to demonstrate meaningful weight loss in humans, leading to the termination of development and a regulatory limbo that restricts its use in the U.S. While it appears safe and well-tolerated, the lack of efficacy and the existence of multiple FDA-approved weight-loss drugs weigh against its adoption as a therapeutic agent. For now, AOD-9604 remains a research chemical—not a medicine—and its use outside of regulated clinical trials is not recommended.

❓ FAQs About AOD-9604

✧ Written in service of evidence-based understanding and scientific integrity ✧